Association of In Vitro Fertilization With Childhood Cancer in the United States.
OA: closed
AI-generated summary
This population-based cohort study found a slightly increased incidence of overall childhood cancers and a higher rate of hepatic tumors among children conceived via IVF compared to naturally conceived children.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
ImportanceIn vitro fertilization (IVF) is associated with birth defects and imprinting disorders. Because these conditions are associated with an increased risk of childhood cancer, many of which originate in utero, descriptions of cancers among children conceived via IVF are imperative.ObjectiveTo compare the incidence of childhood cancers among children conceived in vitro with those conceived naturally.Design, setting, and participantsA retrospective, population-based cohort study linking cycles reported to the Society for Assisted Reproductive Technology Clinical Outcomes Reporting System from January 1, 2004, to December 31, 2012, that resulted in live births from September 1, 2004, to December 31, 2013, to the birth and cancer registries of 14 states, comprising 66% of United States births and 75% of IVF-conceived births, with follow-up from September 1, 2004, to December 31, 2014. The study included 275 686 children conceived via IVF and a cohort of 2 266 847 children, in which 10 births were randomly selected for each IVF birth. Statistical analysis was performed from April 1, 2017, to October 1, 2018.ExposureIn vitro fertilization.Main outcomes and measuresCancer diagnosed in the first decade of life.ResultsA total of 321 cancers were detected among the children conceived via IVF (49.1% girls and 50.9% boys; mean [SD] age, 4.6 [2.5] years for singleton births and 5.9 [2.4] years for multiple births), and a total of 2042 cancers were detected among the children not conceived via IVF (49.2% girls and 50.8% boys; mean [SD] age, 6.1 [2.6] years for singleton births and 4.7 [2.6] years for multiple births). The overall cancer rate (per 1 000 000 person-years) was 251.9 for the IVF group and 192.7 for the non-IVF group (hazard ratio, 1.17; 95% CI, 1.00-1.36). The rate of hepatic tumors was higher among the IVF group than the non-IVF group (hepatic tumor rate: 18.1 vs 5.7; hazard ratio, 2.46; 95% CI, 1.29-4.70); the rates of other cancers did not differ between the 2 groups. There were no associations with specific IVF treatment modalities or indication for IVF.Conclusions and relevanceThis study found a small association of IVF with overall cancers of early childhood, but it did observe an increased rate of embryonal cancers, particularly hepatic tumors, that could not be attributed to IVF rather than to underlying infertility. Continued follow-up for cancer occurrence among children conceived via IVF is warranted.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (3)
- Perinatal outcomes associated with assisted reproductive technology: the Massachusetts Outcomes Study of Assisted Reproductive Technologies (MOSART). 2015
- The TP53 fertility network. 2012
- Association between Beckwith-Wiedemann syndrome and assisted reproductive technology: a case series of 19 patients. 2005
References (37)
- Association between Beckwith-Wiedemann syndrome and assisted reproductive technology: a case series of 19 patients. via crossref
- Perinatal outcomes associated with assisted reproductive technology: the Massachusetts Outcomes Study of Assisted Reproductive Technologies (MOSART). via crossref
- The TP53 fertility network. via crossref
- doi:10.1136/bmj.37957.560278.ee via crossref
- doi:10.1016/j.fertnstert.2010.07.1075 via crossref
- doi:10.1111/j.1471-0528.2010.02517.x via crossref
- doi:10.1002/bdra.20645 via crossref
- doi:10.1016/s0140-6736(07)60456-5 via crossref
- doi:10.1056/nejmoa1008095 via crossref
- doi:10.1371/journal.pone.0069077 via crossref
- doi:10.1016/j.jpeds.2011.12.006 via crossref
- doi:10.1093/aje/kwr470 via crossref
- doi:10.1159/000355544 via crossref
- doi:10.1016/j.maturitas.2013.05.017 via crossref
- doi:10.1016/j.fertnstert.2016.05.026 via crossref
- doi:10.1002/cncr.20910 via crossref
- doi:10.1093/ije/dyu265 via crossref
- doi:10.1002/cncr.v116:12 via crossref
- doi:10.15585/mmwr.ss6703a1 via crossref
- doi:10.1158/1055-9965.epi-08-0660 via crossref
- doi:10.1097/ede.0b013e3181a5a332 via crossref
- doi:10.1016/j.fertnstert.2009.07.986 via crossref
- doi:10.1016/j.fertnstert.2013.03.017 via crossref
- doi:10.1056/nejmoa1301675 via crossref
- doi:10.1093/humrep/deu143 via crossref
- doi:10.1542/peds.2008-3069 via crossref
- doi:10.1146/annurev-animal-022513-114109 via crossref
- doi:10.1073/pnas.1422088112 via crossref
- doi:10.4161/epi.24655 via crossref
- doi:10.1093/humrep/dei405 via crossref
- doi:10.1016/s0022-3476(98)70008-3 via crossref
- doi:10.1111/j.1552-6909.2006.00016.x via crossref
- doi:10.1093/humrep/deh542 via crossref
- doi:10.1002/ijc.v133.5 via crossref
- doi:10.1038/sj.bjc.6605732 via crossref
- doi:10.1016/j.rbmo.2013.10.013 via crossref
- doi:10.1016/s0140-6736(03)13592-1 via crossref
Source provenance
- crossref
- last seen: 2026-09-15T06:33:22.287267+00:00
- europepmc
- last seen: 2026-09-20T09:27:46.357103+00:00
- unpaywall
- last seen: 2026-09-21T07:16:15.697306+00:00